A native of Scotland, Gordon gained his PhD at Glasgow with further training at Ciba Geigy AG, Switzerland and the University of Colorado. He won the Glenn Award for Research in Biological Mechanisms of Aging, a senior scholarship from the Ellison Medical Foundation and the Tenovus Award for Biomedical Research. Gordon serves on many national advisory panels in the UK and USA including the National Institute on Aging’s Board of Scientific Councillors and the Chair of Biological Sciences at the Gerontology Society of America.
Gordon’s lab is focused on understanding the role of aging in the origins of age-related chronic disease. He led the identification of pharmacological interventions in aging by publishing the first pharmacological lifespan extension in an animal in a high-profile journal, prompting many efforts to find compounds that extend lifespan in different animal models.
His lab utilizes molecular genetics, biochemistry, proteomics and metabolomics, as well as C. elegans, which ages rapidly but exhibits many characteristics of human aging, and has identified scores of chemical compounds that suppress disease phenotypes and extend lifespan. Many of these compounds promote protein homeostasis, which usually fails during normal aging and is a factor in diseases such as Alzheimer’s and Parkinson’s.
Gordon has partnered with numerous biotechnology companies in sponsored research agreements and has strong collaborations in pre-clinical aging research on diseases such as osteoporosis and Parkinson’s disease.